These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38910418)

  • 1. The Smart Drug Delivery of Rotigotine Using Transdermal Patch for the Successful Management of Parkinson's Disease.
    Dharmian JP; PushpaNathan ACS; Ramakrishnan P; Subramanian RN; Levy JD; Palani P; Krishnaswami V
    Cent Nerv Syst Agents Med Chem; 2024 Jun; ():. PubMed ID: 38910418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
    Lau YH; Leta V; Rukavina K; Parry M; Ann Natividad J; Metta V; Chung-Faye G; Chaudhuri KR
    J Neural Transm (Vienna); 2022 Jul; 129(7):889-894. PubMed ID: 35503480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
    Cawello W; Braun M; Andreas JO
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):475-481. PubMed ID: 29332198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
    Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
    Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
    Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W
    Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of Polymers-Based Methotrexate Patches and Investigation of the Effect of Various Penetration Enhancers: In Vitro, Ex Vivo and In Vivo Characterization.
    Latif MS; Nawaz A; Rashid SA; Akhlaq M; Iqbal A; Khan MJ; Khan MS; Lim V; Alfatama M
    Polymers (Basel); 2022 May; 14(11):. PubMed ID: 35683883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
    Schnitzler A; Leffers KW; Häck HJ
    Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
    Kim BH; Yu KS; Jang IJ; Soo Lim K; Kim JR; Elshoff JP; Andreas JO; Braun M; Cawello W
    Clin Ther; 2015 Apr; 37(4):902-12. PubMed ID: 25791613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
    Cawello W; Kim SR; Braun M; Elshoff JP; Masahiro T; Ikeda J; Funaki T
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):353-62. PubMed ID: 25773763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.
    Cawello W; Wolff HM; Meuling WJ; Horstmann R; Braun M
    Clin Pharmacokinet; 2007; 46(10):851-7. PubMed ID: 17854234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and Evaluation of Hydrophilic Polymer Based Methotrexate Patches: In Vitro and In Vivo Characterization.
    Latif MS; Al-Harbi FF; Nawaz A; Rashid SA; Farid A; Mohaini MA; Alsalman AJ; Hawaj MAA; Alhashem YN
    Polymers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.